Precision Biosciences (DTIL) Operating Leases (2020 - 2026)

Precision Biosciences (DTIL) has 7 years of Operating Leases data on file, last reported at $6.0 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $6.0 million, changed 0.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.0 million (changed 0.02% YoY), and the FY2025 annual result was $4.9 million, down 23.53% from the prior year.
• Operating Leases advanced to $6.0 million in Q1 2026 per DTIL's latest filing, from $4.9 million in the prior quarter.
• Over five years, Operating Leases peaked at $7.7 million in Q4 2023 and troughed at $1.1 million in Q4 2022.
• A 5-year average of $5.1 million and a median of $5.5 million in 2025 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2022 and 2023: Operating Leases slumped 78.0% in 2022, then surged 629.27% in 2023.
• A 5-year view of Operating Leases shows it stood at $1.1 million in 2022, then surged by 629.27% to $7.7 million in 2023, then slipped by 17.08% to $6.4 million in 2024, then fell by 23.53% to $4.9 million in 2025, then climbed by 23.48% to $6.0 million in 2026.
• Business Quant data shows DTIL's Operating Leases at $6.0 million in Q1 2026, $4.9 million in Q4 2025, and $5.3 million in Q3 2025.